Udenafil

Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008

...ed December 31, 2008 was a $2.0 million expense to acquire certain rights from Dong-A PharmTech Co. Ltd. to develop and market its orally-administered udenafil product for the treatment of erectile dysfunction ("ED"). Excluding this $2.0 million expense in the quarter ended December 31, 2008, R&D increase...

Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment

...WCRX ) today announced that it has signed an agreement with Dong-A PharmTech Co. Ltd., based in Korea, to develop and market their orally-administered udenafil product, a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) in the United States. Dong-A has successfully com...

Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia

...harmTech Co., Ltd. Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil and a number of other drug candidates worldwide outside Korea. Statements under the Private Securities Litigation Reform Act: with the exception of t...

Udenafil in Medical Technology

Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil

SEOUL, South Korea, Feb. 25 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. announced today that its European licensee, Dr. Falk Pharma, has initiated a 200 patient, phase 2 proof of concept clinical study to investigate the use of udenafil, a long acting phosphodiesterase type 5 inhibitor, for por...

Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil, Its New Long Acting Drug For Erectile Dysfunction

...designed to investigate the efficacy and safety of udenafil in patients with ED. Following a 4-week non-drug b...ndomized to one of four treatment groups: Placebo, udenafil 50mg, udenafil 100mg or udenafil 150mg. The drug treatment period...